Developer docs
API playgroundTry for free, no card

Search company profiles

HiberCell

Full company profile

uuid0000s3t

Namestring
HiberCell
Legal namestring
HiberCell Inc.
Websiteurl
hibercell.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

HiberCell is a clinical-stage biotechnology company developing first-in-class oncology therapeutics that modulate the Integrated Stress Response (ISR) and Unfolded Protein Response (UPR) to address cancer relapse, metastasis, and treatment resistance. Founded in 2019 and originally based in New York before relocating to Roseville, Minnesota, the company was built on pioneering tumor dormancy research from Julio Aguirre-Ghiso's lab at Mount Sinai. Its lead assets are HC-7366, a first-in-class selective GCN2 kinase activator in Phase 1b trials for clear cell renal cell carcinoma (in combination with Merck's WELIREG/belzutifan) and acute myeloid leukemia (in combination with venetoclax and azacitidine), and HC-5404, a first-in-class PERK inhibitor that received FDA Fast Track Designation and was partnered in November 2025 with AVEO Oncology (an LG Chem company) for renal cell carcinoma development. HiberCell also acquired Genuity Science (2021) for AI/ML genomics and multi-omic analytics capabilities and Biothera (2020) for the Imprime PGG innate immune program, bringing headcount to 51–100 and cumulative funding to approximately $158 million in equity ($60.75M Series A, $67.4M Series B) plus a $30 million Hercules Capital debt facility.

The company's business model is licensing- and milestone-driven: HiberCell is pre-revenue, with future economics contingent on (i) upfront and milestone payments from strategic partners such as Merck and AVEO/LG Chem, (ii) potential royalties on commercialization, and (iii) eventual direct product revenue if any asset is retained and launched. Clinical operations are conducted through academic medical centers including Memorial Sloan Kettering, MD Anderson, and Sarah Cannon Research Institute. Marketing and stakeholder engagement occur primarily through peer-reviewed publications, presentations at AACR/SITC/ASCO/ASH, and corporate press releases, reflecting a scientific-credibility-driven go-to-market approach typical of clinical-stage biotechs.

Short descriptiontext

HiberCell is a clinical-stage biotechnology company developing first-in-class oncology therapeutics that target the Integrated Stress Response in cancer cells, with two lead candidates—HC-7366 and HC-5404—in Phase 1b trials for renal cell carcinoma and acute myeloid leukemia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics development, integrated stress response targeting, cancer relapse therapeutics, tumor dormancy research, clinical-stage biotechnology
Industry1 code
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-Stage Oncology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development & Commercialization
TypeOne Time License
Description

HiberCell is a clinical-stage biotech focused on developing novel cancer therapeutics. The company does not currently generate revenue. Future revenue would come from commercialization of its drug candidates (HC-7366, HC-5404) upon FDA approval, either directly or through licensing/partnership agreements with pharmaceutical companies.

hibercell.com
2Partnership & Milestone Payments
TypeLicensing Royalties
Description

Through partnerships like the AVEO Oncology agreement, HiberCell receives option fees and is eligible for milestone payments and royalties contingent upon successful development and commercialization of HC-5404.

hibercell.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HiberCell is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics that target adaptive stress pathways — specifically the Integrated Stress Response (ISR) and the Unfolded Protein Response (UPR) — to prevent cancer relapse and metastasis. Its lead candidates HC-7366 (a GCN2 activator) and HC-5404 (a PERK inhibitor) are in Phase 1 clinical trials for clear cell renal cell carcinoma (ccRCC), acute myeloid leukemia (AML), and other solid tumors, with development advanced through partnerships with large pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 study of HC-5404 showed favorable safety profile with maximum tolerated dose not determined; one durable partial response (>2 years duration) and multiple patients with stable disease
+2 more records
Product overview1 text field

HiberCell is a clinical-stage oncology company developing a differentiated pipeline of first-in-class therapeutics targeting adaptive stress pathways to address cancer relapse, metastasis, and treatment resistance. The company's core products include HC-7366 (a GCN2 activator targeting the Integrated Stress Response) and HC-5404 (a PERK inhibitor targeting the Unfolded Protein Response), both in Phase 1b clinical trials for renal cell carcinoma and AML. Additionally, the company has odetiglucan (Imprime PGG) in Phase 2 development for innate immune modulation. The company also acquired Genuity Science to integrate AI/ML capabilities into its drug discovery platform.

Product and service3 records
1HC-5404 (PERK Inhibitor)
CategoryOncology Therapeutic Candidate — PERK Inhibitor
Description

HC-5404 is a first-in-class, first-in-human, selective, orally bioavailable small molecule inhibitor of PERK (PKR-like Endoplasmic Reticulum Kinase), a key enzyme in the Unfolded Protein Response (UPR). It is being developed to block the adaptive survival mechanisms that cancer cells use in harsh tumor microenvironments, initially for renal cell carcinoma in combination with VEGFR-TKIs under an exclusive development and option agreement with AVEO Oncology.

2HC-7366 (GCN2 Activator)
CategoryOncology Therapeutic Candidate — GCN2 Activator
Description

HC-7366 is a first-in-class, first-in-human, selective, orally bioavailable small molecule activator of General Control Nonderepressible 2 (GCN2) kinase, a metabolic stress sensor in the Integrated Stress Response (ISR) pathway. It is in Phase 1b clinical investigation for clear cell renal cell carcinoma (ccRCC), in combination with WELIREG (belzutifan) under a Merck clinical collaboration, and for acute myeloid leukemia (AML), in combination with venetoclax and azacitidine.

3Odetiglucan (Imprime PGG)
CategoryOncology Therapeutic Candidate — Innate Immune Modulator
Description

Odetiglucan, also known as Imprime PGG, is a therapeutic candidate that modulates the anti-tumor innate immune response. It is currently in Phase 2 clinical development, having been brought into HiberCell's pipeline through the Biothera acquisition.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1AVEO Oncology (LG Chem company)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Exclusive development and option agreement for HC-5404 (first-in-human PERK inhibitor) to be developed in combination with AVEO's FOTIVDA (tivozanib) for renal cell carcinoma. AVEO conducts initial clinical development and has option to obtain exclusive license for development, manufacturing, and commercialization worldwide. HiberCell eligible for milestone payments and royalties upon option exercise.

hibercell.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-05
Description

Clinical collaboration to evaluate HC-7366 (GCN2 activator) in combination with WELIREG (belzutifan, HIF-2α inhibitor) in Phase 1b study for clear cell renal cell carcinoma. Merck provides belzutifan supply and clinical collaboration support. Study led by Dr. Robert Motzer at Memorial Sloan Kettering Cancer Center.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-08-16
Description

Acquisition of Genuity Science provides HiberCell with genomics analytics platform, AI/ML capabilities, and approximately $100M in cash. Includes wholly owned subsidiaries Genuity Science (Iceland) ehf and Genuity Sciences (Ireland) Limited. Brings advanced multi-omic analytics and datasets in cancer, cardiometabolic, autoimmune, and neurological disorders.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase 1b study of HC-7366 with belzutifan; Dr. Robert Motzer serves as lead Principal Investigator.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase 1b study of HC-7366 in AML; Dr. Abhishek Maiti serves as Principal Investigator.

6Sarah Cannon Research Institute at Tennessee Oncology
Strategic tierMinorTypeStrategic or Co-development Partner
Description

First clinical trial site opened for Phase 1a/b trial of HC-7366 in advanced solid tumors in Nashville, Tennessee.

hibercell.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology biotech with multiple first-in-class small molecule programs in Phase 1/2 development, mirroring HiberCell's stage and modality.

TypeDirect peer
Description

Clinical-stage oncology biotech developing targeted small molecules (e.g., menin inhibitors) for solid tumors and hematologic malignancies, with overlapping indication set including head and neck cancer.

TypeDirect peer
Description

Clinical-stage oncology company targeting chromatin regulatory biology with first-in-class small molecules, analogous to HiberCell's first-in-class stress-pathway approach.

TypeDirect peer
Description

Clinical-stage immuno-oncology biotech with multiple Phase 1/2 assets and large-pharma partnership experience (Gilead), comparable in scale and partnering strategy to HiberCell.

TypeDirect peer
Description

Clinical-stage precision oncology biotech combining computation with structure-based drug design, overlapping HiberCell's emphasis on novel mechanism discovery and first-in-class positioning.

TypeDirect peer
Description

Clinical-stage precision oncology biotech focused on synthetic lethality with partnered assets, comparable in clinical-stage maturity and oncology focus to HiberCell.

TypeDirect peer
Description

Clinical-stage precision oncology biotech developing small molecule therapies against novel oncogenic targets, with similar pipeline profile and indication breadth.

TypeDirect peer
Description

Clinical-stage precision oncology biotech with multiple small molecule programs targeting the RAS/MAPK pathway, sharing HiberCell's first-in-class small molecule oncology profile.

TypeEmerging player
Description

Computational drug discovery platform with a growing clinical-stage oncology pipeline; overlaps with HiberCell's AI/ML capability acquired from Genuity Science.

TypeEmerging player
Description

AI-driven drug discovery company with clinical-stage oncology assets, providing a comparable model for technology-enabled biotech pipeline development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HiberCell

Clinical-Stage Oncology Therapeuticshibercell.com

HiberCell is a clinical-stage biotechnology company developing first-in-class oncology therapeutics that target the Integrated Stress Response in cancer cells, with two lead candidates—HC-7366 and HC-5404—in Phase 1b trials for renal cell carcinoma and acute myeloid leukemia.

What HiberCell does

HiberCell is a clinical-stage biotechnology company developing first-in-class oncology therapeutics that modulate the Integrated Stress Response (ISR) and Unfolded Protein Response (UPR) to address cancer relapse, metastasis, and treatment resistance. Founded in 2019 and originally based in New York before relocating to Roseville, Minnesota, the company was built on pioneering tumor dormancy research from Julio Aguirre-Ghiso's lab at Mount Sinai. Its lead assets are HC-7366, a first-in-class selective GCN2 kinase activator in Phase 1b trials for clear cell renal cell carcinoma (in combination with Merck's WELIREG/belzutifan) and acute myeloid leukemia (in combination with venetoclax and azacitidine), and HC-5404, a first-in-class PERK inhibitor that received FDA Fast Track Designation and was partnered in November 2025 with AVEO Oncology (an LG Chem company) for renal cell carcinoma development. HiberCell also acquired Genuity Science (2021) for AI/ML genomics and multi-omic analytics capabilities and Biothera (2020) for the Imprime PGG innate immune program, bringing headcount to 51–100 and cumulative funding to approximately $158 million in equity ($60.75M Series A, $67.4M Series B) plus a $30 million Hercules Capital debt facility.

The company's business model is licensing- and milestone-driven: HiberCell is pre-revenue, with future economics contingent on (i) upfront and milestone payments from strategic partners such as Merck and AVEO/LG Chem, (ii) potential royalties on commercialization, and (iii) eventual direct product revenue if any asset is retained and launched. Clinical operations are conducted through academic medical centers including Memorial Sloan Kettering, MD Anderson, and Sarah Cannon Research Institute. Marketing and stakeholder engagement occur primarily through peer-reviewed publications, presentations at AACR/SITC/ASCO/ASH, and corporate press releases, reflecting a scientific-credibility-driven go-to-market approach typical of clinical-stage biotechs.

HiberCell firmographics

Firmographics
Name
HiberCell
Legal name
HiberCell Inc.
Website
https://hibercell.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
HiberCell is a clinical-stage biotechnology company developing first-in-class oncology therapeutics that target the Integrated Stress Response in cancer cells, with two lead candidates—HC-7366 and HC-5404—in Phase 1b trials for renal cell carcinoma and acute myeloid leukemia.
Ownership category
akta.pro rank

HiberCell industry classification

Industry
Product category
Clinical-Stage Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology therapeutics development
  • Integrated stress response targeting
  • Cancer relapse therapeutics
  • Tumor dormancy research
  • Clinical-stage biotechnology

Where HiberCell is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

HiberCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Therapeutic Development & Commercialization: HiberCell is a clinical-stage biotech focused on developing novel cancer therapeutics. The company does not currently generate revenue. Future revenue would come from commercialization of its drug candidates (HC-7366, HC-5404) upon FDA approval, either directly or through licensing/partnership agreements with pharmaceutical companies.
  2. Partnership & Milestone Payments: Through partnerships like the AVEO Oncology agreement, HiberCell receives option fees and is eligible for milestone payments and royalties contingent upon successful development and commercialization of HC-5404.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

HiberCell product offering

Product offering

Core offering

HiberCell is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics that target adaptive stress pathways — specifically the Integrated Stress Response (ISR) and the Unfolded Protein Response (UPR) — to prevent cancer relapse and metastasis. Its lead candidates HC-7366 (a GCN2 activator) and HC-5404 (a PERK inhibitor) are in Phase 1 clinical trials for clear cell renal cell carcinoma (ccRCC), acute myeloid leukemia (AML), and other solid tumors, with development advanced through partnerships with large pharmaceutical companies.

Product overview

HiberCell is a clinical-stage oncology company developing a differentiated pipeline of first-in-class therapeutics targeting adaptive stress pathways to address cancer relapse, metastasis, and treatment resistance. The company's core products include HC-7366 (a GCN2 activator targeting the Integrated Stress Response) and HC-5404 (a PERK inhibitor targeting the Unfolded Protein Response), both in Phase 1b clinical trials for renal cell carcinoma and AML. Additionally, the company has odetiglucan (Imprime PGG) in Phase 2 development for innate immune modulation. The company also acquired Genuity Science to integrate AI/ML capabilities into its drug discovery platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • HC-5404 (PERK Inhibitor) HC-5404 is a first-in-class, first-in-human, selective, orally bioavailable small molecule inhibitor of PERK (PKR-like Endoplasmic Reticulum Kinase), a key enzyme in the Unfolded Protein Response (UPR). It is being developed to block the adaptive survival mechanisms that cancer cells use in harsh tumor microenvironments, initially for renal cell carcinoma in combination with VEGFR-TKIs under an exclusive development and option agreement with AVEO Oncology.
  • HC-7366 (GCN2 Activator) HC-7366 is a first-in-class, first-in-human, selective, orally bioavailable small molecule activator of General Control Nonderepressible 2 (GCN2) kinase, a metabolic stress sensor in the Integrated Stress Response (ISR) pathway. It is in Phase 1b clinical investigation for clear cell renal cell carcinoma (ccRCC), in combination with WELIREG (belzutifan) under a Merck clinical collaboration, and for acute myeloid leukemia (AML), in combination with venetoclax and azacitidine.
  • Odetiglucan (Imprime PGG) Odetiglucan, also known as Imprime PGG, is a therapeutic candidate that modulates the anti-tumor innate immune response. It is currently in Phase 2 clinical development, having been brought into HiberCell's pipeline through the Biothera acquisition.

Quantifiable outcome

  • Phase 1 study of HC-5404 showed favorable safety profile with maximum tolerated dose not determined; one durable partial response (>2 years duration) and multiple patients with stable disease
  • +2 more outcomes

Companies that use HiberCell

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

HiberCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

HiberCell partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • AVEO Oncology (LG Chem company)coreStrategic or Co-development Partner · 4 November 2025Exclusive development and option agreement for HC-5404 (first-in-human PERK inhibitor) to be developed in combination with AVEO's FOTIVDA (tivozanib) for renal cell carcinoma. AVEO conducts initial clinical development and has option to obtain exclusive license for development, manufacturing, and commercialization worldwide. HiberCell eligible for milestone payments and royalties upon option exercise.
  • Merck (MSD outside US and Canada)coreStrategic or Co-development Partner · 5 December 2023Clinical collaboration to evaluate HC-7366 (GCN2 activator) in combination with WELIREG (belzutifan, HIF-2α inhibitor) in Phase 1b study for clear cell renal cell carcinoma. Merck provides belzutifan supply and clinical collaboration support. Study led by Dr. Robert Motzer at Memorial Sloan Kettering Cancer Center.
  • Genuity Science, Inc.coreTechnology or Integration · 16 August 2021Acquisition of Genuity Science provides HiberCell with genomics analytics platform, AI/ML capabilities, and approximately $100M in cash. Includes wholly owned subsidiaries Genuity Science (Iceland) ehf and Genuity Sciences (Ireland) Limited. Brings advanced multi-omic analytics and datasets in cancer, cardiometabolic, autoimmune, and neurological disorders.
  • Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerClinical trial site for Phase 1b study of HC-7366 with belzutifan; Dr. Robert Motzer serves as lead Principal Investigator.
  • MD Anderson Cancer CenterminorStrategic or Co-development PartnerClinical trial site for Phase 1b study of HC-7366 in AML; Dr. Abhishek Maiti serves as Principal Investigator.
  • Sarah Cannon Research Institute at Tennessee OncologyminorStrategic or Co-development PartnerFirst clinical trial site opened for Phase 1a/b trial of HC-7366 in advanced solid tumors in Nashville, Tennessee.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

HiberCell competitors and assessment

Company assessment

Direct peers

  • IDEAYA Biosciences: Clinical-stage precision oncology biotech with multiple first-in-class small molecule programs in Phase 1/2 development, mirroring HiberCell's stage and modality.
  • Kura Oncology: Clinical-stage oncology biotech developing targeted small molecules (e.g., menin inhibitors) for solid tumors and hematologic malignancies, with overlapping indication set including head and neck cancer.
  • Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulatory biology with first-in-class small molecules, analogous to HiberCell's first-in-class stress-pathway approach.
  • Arcus Biosciences: Clinical-stage immuno-oncology biotech with multiple Phase 1/2 assets and large-pharma partnership experience (Gilead), comparable in scale and partnering strategy to HiberCell.
  • Relay Therapeutics: Clinical-stage precision oncology biotech combining computation with structure-based drug design, overlapping HiberCell's emphasis on novel mechanism discovery and first-in-class positioning.
  • Repare Therapeutics: Clinical-stage precision oncology biotech focused on synthetic lethality with partnered assets, comparable in clinical-stage maturity and oncology focus to HiberCell.
  • Black Diamond Therapeutics: Clinical-stage precision oncology biotech developing small molecule therapies against novel oncogenic targets, with similar pipeline profile and indication breadth.
  • Erasca: Clinical-stage precision oncology biotech with multiple small molecule programs targeting the RAS/MAPK pathway, sharing HiberCell's first-in-class small molecule oncology profile.

Emerging players

  • Schrödinger, Inc. Computational drug discovery platform with a growing clinical-stage oncology pipeline; overlaps with HiberCell's AI/ML capability acquired from Genuity Science.
  • Recursion Pharmaceuticals: AI-driven drug discovery company with clinical-stage oncology assets, providing a comparable model for technology-enabled biotech pipeline development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

HiberCell social profiles

Digital presence

HiberCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HiberCell leadership team

Management profile

Number of profiles

Profiles11 records

HiberCell subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

HiberCell funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HiberCell M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HiberCell

What does HiberCell do?

HiberCell is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics that target adaptive stress pathways — specifically the Integrated Stress Response (ISR) and the Unfolded Protein Response (UPR) — to prevent cancer relapse and metastasis. Its lead candidates HC-7366 (a GCN2 activator) and HC-5404 (a PERK inhibitor) are in Phase 1 clinical trials for clear cell renal cell carcinoma (ccRCC), acute myeloid leukemia (AML), and other solid tumors, with development advanced through partnerships with large pharmaceutical companies.

Is HiberCell a public or private company?

HiberCell is a private company. It is classified as venture growth investor backed and is currently operating.

When was HiberCell founded?

HiberCell was founded in 2019. It employs 11 to 50 people.

Where is HiberCell based?

HiberCell is headquartered in New York, United States, in the North America region.

How does HiberCell make money?

Two revenue lines are on record. Therapeutic Development & Commercialization is the primary driver. The others are partnership & Milestone Payments.

Who are HiberCell's main competitors?

Direct peers on record are IDEAYA Biosciences, Kura Oncology, Foghorn Therapeutics, Arcus Biosciences, Relay Therapeutics, Repare Therapeutics, Black Diamond Therapeutics and Erasca. Emerging players are Schrödinger, Inc. and Recursion Pharmaceuticals.

Does HiberCell have an API?

No public API is recorded for HiberCell.

What industry is HiberCell in?

HiberCell's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Irish TimesCompany selling DNA data boosts profits to nearly €5m as it scales back Irish operationsGenuity Science Ireland reported pretax profits of €4.88 million in 2025, up 24% from 2024, with revenue of $6.87 million, up 17.73%. The Dublin-based firm, owned by HiberCell, is scaling back operations and has no R&D expenses.BioSpaceHiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)HiberCell announced preclinical data showing HC-7366 enhances VEGFR-TKI activity in clear cell renal cell carcinoma, outperforming VEGFR-TKI/HIF-2i combinations. The data support a Phase 1b arm evaluating HC-7366 with cabozantinib, and the findings will be presented at the AACR Annual Meeting 2026.PR NewswireAVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human CompoundAVEO Oncology and HiberCell have entered an exclusive development and option agreement to develop HiberCell's first-in-human PERK inhibitor, HC-5404, in combination with AVEO's approved renal cell carcinoma drug FOTIVDA. Under the deal, AVEO will conduct initial clinical development and holds the option to secure an exclusive global license for HC-5404 upon payment of a fee and potential milestone payments.GlobeNewswireHiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear CHiberCell and Merck announced a Phase 1b study to evaluate HC-7366, a GCN2 kinase activator, combined with belzutifan in clear cell renal cell carcinoma. The study will enroll up to 80 patients and open in Q1 2024, with Robert Motzer as lead PI. The combination aims to broaden responses beyond belzutifan alone.GlobeNewswireHiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in CombinationsHiberCell completed its Phase 1 study of PERK inhibitor HC-5404 in solid tumors, reporting favorable safety and dose-dependent exposure. Preliminary efficacy included one durable partial response and 17.4% of patients remaining on therapy over 180 days. The company is seeking partners to advance HC-5404 in combination with VEGFR TKIs.The Irish TimesFuture of Genuity’s Irish DNA database is worryingly uncertainThe future of Genuity Science Ireland's genomic database is uncertain following financial losses that threaten its funding from parent company HiberCell. The article highlights concerns over the use of taxpayer funds and controversial consent mechanisms for collecting DNA samples, with critics calling for the data to be transferred to a new public infrastructure project. Meanwhile, the Irish government has launched Genomics Data Infrastructure (GDI) Ireland to establish secure national standards for managing genetic data.GlobeNewswireHiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal AdenocarcinomHiberCell dosed the first patient in a Phase 1b trial of odetiglucan combined with CDX-1140 in metastatic pancreatic ductal adenocarcinoma. The study aims to identify the maximum tolerated dose and evaluate safety and efficacy, with interim data expected in the second half of 2023.GlobeNewswireHiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023HiberCell announced three preclinical poster presentations at the AACR Annual Meeting 2023 for its PERK inhibitor HC-5404 and GCN2 activator HC-7366. The data show activity in solid tumors, including RCC and HNSCC, with HC-5404 in combination with anti-angiogenic TKIs and HC-7366 as monotherapy or with standard agents. Both compounds are in Phase 1a clinical trials.GlobeNewswireHiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)HiberCell announced preclinical data showing HC-7366, a GCN2 activator, showed strong antitumor activity in AML models, including 100% complete response and 100% tumor growth inhibition. The company received FDA clearance for a Phase 1b clinical trial of HC-7366 in AML, with plans to initiate the trial after completing a solid tumor study.GlobeNewswireHiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingHiberCell announced two clinical abstract poster presentations at the SITC 37th Annual Meeting in Boston, November 8-12, 2022. The posters cover GCN2 activator HC-7366 and PERK inhibitor HC-5404, with Phase 1 trials ongoing for both candidates.